Literature DB >> 26438444

T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition.

Roch Houot1, Liora Michal Schultz2, Aurélien Marabelle3, Holbrook Kohrt4.   

Abstract

Tumor immunotherapy has had demonstrable efficacy in patients with cancer. The most promising results have been with T-cell-based therapies. These include adoptive cell transfer of tumor-infiltrating lymphocytes, genetically engineered T cells, and immune checkpoint inhibitor antibodies. In this review, we describe the different T-cell-based strategies currently in clinical trials and put their applications, present and future, into perspective. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26438444     DOI: 10.1158/2326-6066.CIR-15-0190

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  55 in total

1.  Ewing sarcoma partial regression without GvHD by chondromodulin-I/HLA-A*02:01-specific allorestricted T cell receptor transgenic T cells.

Authors:  Uwe Thiel; Sebastian J Schober; Ingo Einspieler; Andreas Kirschner; Melanie Thiede; David Schirmer; Katja Gall; Franziska Blaeschke; Oxana Schmidt; Susanne Jabar; Andreas Ranft; Rebeca Alba Rubío; Uta Dirksen; Thomas G P Grunewald; Poul H Sorensen; Günther H S Richter; Irene Teichert von Lüttichau; Dirk H Busch; Stefan E G Burdach
Journal:  Oncoimmunology       Date:  2017-04-12       Impact factor: 8.110

Review 2.  Contemporary management of patients with penile cancer and lymph node metastasis.

Authors:  Andrew Leone; Gregory J Diorio; Curtis Pettaway; Viraj Master; Philippe E Spiess
Journal:  Nat Rev Urol       Date:  2017-04-11       Impact factor: 14.432

Review 3.  A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice.

Authors:  Amir Jazaeri; Robert L Coleman; Anil K Sood; Michael M Frumovitz; Pamela T Soliman; Aaron Shafer; Jeffry J Cutrera; Marlana Klinger; Sara E Sharafi; Cynae A L Johnson; Valerie F Villanueva; Emily M Hinchcliff; Andrea Dickens; Katherine E Cain; Jaime E Anderson; Karen H Lu; Shannon N Westin
Journal:  Gynecol Oncol       Date:  2018-09-10       Impact factor: 5.482

Review 4.  Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies.

Authors:  Jeong A Park; Nai-Kong V Cheung
Journal:  Cancer Treat Rev       Date:  2017-06-01       Impact factor: 12.111

Review 5.  Immunotherapy in Gynecologic Cancers: Are We There Yet?

Authors:  Janelle B Pakish; Amir A Jazaeri
Journal:  Curr Treat Options Oncol       Date:  2017-08-24

Review 6.  Current status of engineered T-cell therapy for synovial sarcoma.

Authors:  Matthew Dallos; William D Tap; Sandra P D'Angelo
Journal:  Immunotherapy       Date:  2016-09       Impact factor: 4.196

7.  Current Status of Immunology Education in US Schools and Colleges of Pharmacy.

Authors:  Yuan Zhao; Dana Ho; Benjamin Oldham; Bonnie Dong; Daniel Malcom
Journal:  Am J Pharm Educ       Date:  2019-09       Impact factor: 2.047

8.  Endogenous T cells prevent tumor immune escape following adoptive T cell therapy.

Authors:  Scott R Walsh; Boris Simovic; Lan Chen; Donald Bastin; Andrew Nguyen; Kyle Stephenson; Talveer S Mandur; Jonathan L Bramson; Brian D Lichty; Yonghong Wan
Journal:  J Clin Invest       Date:  2019-12-02       Impact factor: 14.808

Review 9.  Pharmacodynamic Drug-Drug Interactions.

Authors:  Jin Niu; Robert M Straubinger; Donald E Mager
Journal:  Clin Pharmacol Ther       Date:  2019-04-26       Impact factor: 6.875

Review 10.  Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases.

Authors:  Joseph G Skeate; Andrew W Woodham; Mark H Einstein; Diane M Da Silva; W Martin Kast
Journal:  Hum Vaccin Immunother       Date:  2016-02-02       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.